BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tenofovir 1% vaginal gel: Interim Phase IIb data

NIH's National Institute of Allergy and Infectious Diseases (NIAID) discontinued the tenofovir 1% vaginal gel arm in the open-label, African Phase IIb VOICE (MTN-003) trial after an interim analysis conducted by an independent DSMB showed that there was no difference in incidence of new HIV infections vs. placebo gel (6% vs. 6.1%). The placebo gel arm will also be discontinued. The remaining arms - oral...

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >